SEC Form 4 · accession 0000899243-17-027853
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas T. Sheehy
Officer — See Remarks
Period of report
Nov 30, 2017
Accepted (ET)
Dec 4, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Nov 30, 2017 | M | 3,750 | $19.63 | A | 3,750 | D | |
| Common Stock, $0.0001 par value | Nov 30, 2017 | S | 3,750 | $37.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $19.63 | Nov 30, 2017 | M | 3,750 | D | — | Feb 24, 2027 | Common Stock | 3,750 | 73,125 | D |
Explanation of responses
- F1This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- F2The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Remarks
General Counsel and Corporate Secretary